SOURCE: StockCall

StockCall

September 06, 2011 08:10 ET

Analyst Research on Mylan Inc. and Watson Pharmaceuticals Inc. - Generic Drugs Sector Benefits From Patent Cliff

JOHANNESBURG, SOUTH AFRICA--(Marketwire - Sep 6, 2011) - www.stockcall.com/ offers investors comprehensive research on the Drugs - Generic industry and has completed analytical research on Mylan Inc. (NASDAQ: MYL) and Watson Pharmaceuticals Inc. (NYSE: WPI). Register with us today at www.stockcall.com/ to have free access to these researches.

While branded drug makers everywhere have to enact new measures to sustain their businesses as several major patent cliffs loom, companies in the generic drugs sector stand to benefit from their loss. As these drugs become available for copies, companies like Mylan Inc. and Watson Pharmaceuticals Inc. are able to expand their revenues by selling new, less expensive versions of the branded products. Investors looking for free research on Mylan Inc. and Watson Pharmaceuticals Inc. are welcome to sign up at www.stockcall.com/MYL060911.pdf or www.stockcall.com/WPI060911.pdf for our new reports.

www.stockcall.com/ is an online platform where investors doing their due-diligence on the Drugs - Generic industry can have easy and free access to our analyst research and opinions on Mylan Inc. and Watson Pharmaceuticals Inc.; all investors need to do is register for a complimentary membership at https://stockcall.com/development/stockcall/page.php?name=register.html.

Considering the sorry state of consumer confidence, companies that can offer less expensive versions of virtually anything stand to gain in the current environment. Register now at https://stockcall.com/development/stockcall/page.php?name=register.html to have free access to our reports on the Drugs - Generic industry.

The sector has generally very thin margins, however. This has made some of its interactions with the FDA difficult as branded drug companies have generally paid to increase the speed at which their products receive approval. There is a new potential deal in the works that would give $299 million a year in new funding to the FDA that would help speed the generic sector's cause, though. This would only further the strong position many companies are in currently. Visit www.stockcall.com/ to see how companies in this industry have grown over the past years and how they are expected to perform in the future.

About StockCall.com
StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.

Contact Information